The re­verse merg­er par­ty is still buzzing. This time, it's a car­dio and en­docrine start­up with two drugs in Phase 2 and a biotech work­ing...

Roche’s T cell en­gager Lun­sumio has passed a Phase 3 tri­al in a slow-grow­ing type of blood can­cer, clear­ing the path for full ap­proval and...

Plus news about Al­tis Labs, Ma­tisse Phar­ma­ceu­ti­cals, As­traZeneca, No­vo, Longeveron, Con­nexus Ther­a­peu­tics and Avac­ta.

A new Parkin­son’s biotech: The Michael J. Fox Foun­da­tion is sup­port­ing...

Or­bis Med­i­cines will help No­vo cre­ate macro­cy­cles — those ring-shaped mol­e­cules that mar­ry the best of an­ti­bod­ies and small mol­e­cules — for car­diometa­bol­ic dis­eases as...

Bavar­i­an Nordic has ap­point­ed a vet­er­an of Sanofi, As­traZeneca and Pfiz­er to re­place Paul Chap­lin as pres­i­dent and CEO.

Tar­ja Sten­vall will take the helm...